Ron Ram

Country flagIsrael

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

In REACH3 (ClinicalTrials.gov identifier: NCT03112603 ), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.

Year:

2025

Objectives To evaluate the role of additional chemotherapy before autologous hematopoietic cell transplantation (HCT) in patients with relapse/refractory diffuse large B‐cell lymphoma (DLBCL) who achieve partial remission following first salvage therapy. Methods We conducted a multicenter retrospective study of all adult patients with DLBCL who underwent HCT between 2008 and 2020 and achieved partial response (PR) after the first salvage and were either referred directly to HCT ( n = 47) or received additional salvage therapy before HCT ( n = 22). Results Post‐HCT CR rate and progression‐free survival were comparable between the two groups (66% vs. 68%, p = .86 and median not reached vs. 10.2 months [95% confidence interval, CI 7.1–12.3], p = .27, respectively). Median overall survival (OS) and estimated 3‐year OS favored patients who were directly referred to HCT (105.8 [95% CI 63–148] months vs. 14.5 [95% CI 0–44] months, p = .035, and 65% [95% CI 51%–75%] vs. 40% [95% CI 21%–53%], p = .035, respectively). In Cox regression model, while International Prognostic Index and primary refractory versus relapse disease did not impact OS, allocation to a second salvage regimen and older age were both associated with inferior survival (hazard ratio [HR] = 2.57 95% CI 1.1–5.8, p = .023 and HR = 1.04 95% CI 0.99–1.2, p = .064, respectively). Conclusions Referring patients with chemotherapy‐sensitive disease in PR directly to HCT is associated with better OS compared to those receiving additional lines of treatment.

Year:

2022

Collaborators (7)

Peter Vandenberghe

KU Leuven

BELGIUM
View details

Domenico Russo

University of Brescia

ITALY
View details

Robert Zeiser

Director Div. of Tumor immunology/Professor

University Medical Center Freiburg

GERMANY
View details

Ronjon Chakraverty

Professor of Haematology

University of Oxford

UNITED KINGDOM
View details

Robin Sanderson

Honorary Senior Lecturer

King’s College London

UNITED KINGDOM
View details

Simona Pagliuca

Faculty member / Enseignant-chercheur / Enseignante-chercheuse

Université de Lorraine

FRANCE
View details

Laurence de Leval

Director of the Institute of Pathology / Professor of Pathology

Lausanne University Hospital

SWITZERLAND
View details